

Title: Reasons for failed trials of disease-modifying treatments for Alzheimer Disease and their contribution in recent research

Article type: review

Authors: Konstantina G. Yiannopoulou¹, Aikaterini I. Anastasiou², Venetia Zachariou³, SH Pelidou⁴

¹ Memory Center, Neurological Department, Henry Dunant Hospital Center, Athens, Greece.

² Medical School of Athens, National and Kapodistrian University of Athens, Greece.

³ Icahn School of Medicine at Mount Sinai, Nash family Department of Neurosciences, Department of Pharmacological Sciences, and Friedman Brain Institute, New York, USA

⁴ Department of Neurology, University of Ioannina, University Hospital of Ioannina, Ioannina, Greece

Corresponding author: Konstantina G. Yiannopoulou, MD, PhD, Neurological Department, Henry Dunant Hospital Center, 107 Mesogeion Avenue, Athens 11526, E-mail: k.giannopoulou.14@hotmail.com

ABSTRACT

Despite all scientific efforts and many protracted and expensive clinical trials, no new drug has been approved by FDA for treatment of Alzheimer disease (AD) since 2003. Indeed, more than 200 investigational programs have failed or have been abandoned in the last decade. The most probable explanations for failures of disease-modifying treatments (DMTs) for AD may include late initiation of treatments during the course of AD development, inappropriate drug dosages, erroneous selection of treatment targets, and mainly an inadequate understanding of the complex pathophysiology of AD, which may necessitate combination treatments rather than monotherapy. Clinical trials' methodological issues have also been criticized.

Current drug-development research for AD is aimed to overcome these drawbacks. Preclinical and prodromal AD populations, as well as traditionally investigated populations representing all the clinical stages of AD, are included in recent trials. Systematic use of biomarkers in staging preclinical and prodromal AD and of a single primary outcome in trials of prodromal AD are regularly integrated. The application of amyloid, tau, and neurodegeneration biomarkers, including new biomarkers—such as Tau positron emission tomography, neurofilament light chain (blood and CSF biomarker of axonal degeneration) and neurogranin (CSF biomarker of synaptic functioning)—to clinical trials allows more precise staging of AD. Additionally, use of the Bayesian statistics, modifiable clinical trial designs, and clinical trial simulators enrich the trial methodology. Besides, combination therapy regimens are currently assessed in clinical trials.

The abovementioned diagnostic and statistical advances, which have been recently integrated in clinical trials, are consequential to the recent failures of studies of disease-modifying treatments. Their experiential rather than theoretical origins may better equip potentially successful drug-development strategies.

Keywords: Alzheimer's disease, clinical trial fails, disease-modifying treatments, Alzheimer's disease biomarkers, combination treatment, clinical trial designs

Introduction

Given the fact that AD concerns mostly people older than 65 years, the increasing expansion of life span, leads to a fast growing number of AD patients [1]. Consequently, the research focused on AD modifying treatments has become intensively growing. However, despite all arduous research efforts, at the moment there are no effective treatment options for the disease [2,3]. Indeed, no new drug has been approved by FDA for treatment of AD since 2003, although more than 200 therapeutic agents have been assessed in failed or abandoned investigational programs [4,5].

Many explanations for failures of candidate DMTs for AD have been proposed. The most prominent include late initiation of treatments during the course of AD development, inappropriate drug dosages, wrong selection of main treatment targets, and mainly an inadequate understanding of the complex pathophysiology of AD [6]. A novel approach to the treatment problems seems to necessitate combination treatments rather than monotherapy [7]. Clinical trials' methodological issues have also been criticized [4].

Current drug-development research for AD is aimed to overcome these drawbacks. Preclinical and prodromal AD populations, as well as patients representing all the clinical stages of AD, are included in recent trials [8]. Current guidance provided by the US Food and Drug Administration (FDA) for clinical trials in AD further includes use of biomarkers in staging preclinical and prodromal AD and of a single primary outcome in trials of prodromal AD, and additionally the use of Bayesian statistics and modifiable clinical trial designs [3]. Besides, combination therapy regimens are currently assessed in clinical trials [7].

This review aims to further contribute to the understanding of different reasons that are responsible for the failures of clinical trials for AD. It will also try to investigate how the lessons of these failures are integrated as knowledge and gained experience in new trials.

Explanations for failures of candidate DMTs for AD and the consequent shift in current clinical trials

a. Inadequate understanding of the complex pathophysiology of AD: wrong selection of main treatment target and inappropriate drug dosages

Since lack of efficacy of all agents that were studied in phase 3 trials cannot be accurately explained at this time, it is obvious that the current science is not sufficiently advanced and investigators need to recognize the possibility of deficiency of our knowledge.

Multiple phase 3 failures of agents that aim to reduce beta-amyloid plaques made researchers to abandon the singular focus on amyloid cascade model. Indeed, if patients in anti-amyloid trials are initially positive for high levels of amyloid and although the anti-amyloid drug clears amyloid while finally there is no cognitive benefit, it is reasonable to suggest that pathology or pathophysiology other than singular amyloid needs to be selected as a target [9, 10].

Some of the recent failures in phase 3 studies of anti-amyloid agents in patients with early stage, mild or mild to moderate Alzheimer's disease involved Semagacestat [11], Bapineuzumab [12] and Solanezumab [13].

Further examples of agents targeting beta-amyloid that failed due to lack of efficacy include the β secretase inhibitors (BACE) Lanabecestat [14], Lerubecestat [15] and Atabecestat [16]. These drugs target the β site amyloid-precursor-protein-cleaving enzyme-1 (BACE-1), and although they demonstrated proof of mechanism of action by lowering the plasma and CSF biomarkers A β 40 and A β 42, they failed to prove clinical benefit. The clinical trial of Verubecestat in mild to moderate AD was terminated early due to lack of efficacy. A more recent Verubecestat trial targeting patients with prodromal AD showed even more disappointing results. Adverse events, cognition and daily function worsening were more common in the Verubecestat groups than in the placebo group [15].

In current research a more equipotential conceptualization of AD has been adopted. Amyloid pathology is still targeted, but tau pathology seems maybe more firmly and earlier associated with cognitive decline. At the same time, other pathologies such as arteriosclerosis, blood-brain barrier dysfunction or α -synuclein are also investigated [9]. Ongoing clinical trials assess DMTs with amyloid-related mechanisms, Tau-related mechanisms, and DMTs with other mechanisms such as neuroprotection, anti-inflammatory effects, growth factor promotion, metabolic effects, stem cell therapies [3,5].

b. Inadequate understanding of the complex pathophysiology of AD: late initiation of treatments during the course of AD development

Abnormal deposits of amyloid β and tau tangles and the consequence damage to the brain is believed to start a decade or more before apparent cognitive decline [17].

The lack of efficacy observed in previous phase 3 trials raised the question whether treating AD patients once they become symptomatic may be too late to reverse the progress of neurodegeneration. It is hypothesized that presymptomatic intervention may halt or delay the progression of the disease [10].

The ongoing development of amyloid targeted agents is a direct result of the previous hypothesis. Although all of the previous agents of this category failed in clinical trials, most of the new agents among them are studied in asymptomatic subjects at risk of developing AD [3, 18]. Ongoing clinical trials with active or passive immunotherapy agents [19], with agents that reduce the A β -plaque burden [20, 21], with α -Secretase Modulators [22] and with BACE inhibitors [18] are enrolling prodromal or mild AD patients to test the hypothesis of early interception [3, 10].

Hence, the challenge of DMT development for AD has become more complicated as trial populations include also preclinical and prodromal AD, besides AD dementia patients [23]. Accurate classification of stages of AD, especially preclinical stages, demand a new research framework for the diagnosis of AD that may serve clinical trials of DMTs. in AD [23]. Such a framework based on amyloid, tau, and neurodegeneration biomarkers was introduced by the National Institute on Aging (NIA) and the Alzheimer's Association [24]. Consequently, most of the current clinical trials have integrated the use of fluid [25] or imaging [26] biomarkers. Cerebrospinal fluid (CSF) or blood fluid biomarkers lead the effort to enable more effective DMTs development in AD. Their context of use in clinical trials includes patient selection, patient's classification in a disease state, clarification of therapeutic agent's mechanism of action, appropriate dose selection and measurement of treatment response [27].

CSF biomarkers that are currently used in clinical trials are amyloid beta 42 (A β 42), total tau (t-tau), and tau phosphorylated at threonine 181 (p-tau) identifying subjects at risk of developing AD [26]. The combination of these biomarkers displays sensitivity of 95% and specificity of 83% in detecting subjects that will develop AD[28], hence it is the main patient-selection tool in trials [25, 29].

An ongoing effort for identification of additional fluid biomarkers is remarked. Current research need them for subject enrichment, drug efficiency monitoring, risk classification and prognosis. Several novel biomarkers have been investigated with the aim to be integrated into drug development programmes [30]:

Novel fluid biomarkers of A β metabolism and aggregation

CSF A β 38: It has the promise to be used for patient selection and to demonstrate target engagement of γ -secretase modulators. Commercial assays are already available for this biomarker [25, 31].

Plasma BACE1 activity shows ability for prognosis and patient selection. Commercial assays are already available for both BACE1 protein levels and BACE1 activity [32].

- *Vascular system's novel fluid biomarkers*

CSF and serum Heart-type fatty acid-binding protein (hFABP) could attribute to patient selection and prognosis. Commercial assays are available for hFABP [33].

Novel fluid biomarkers of inflammation and glial activation

CSF and peripheral blood Triggering receptor expressed on myeloid cells 2 (TREM2) has been observed in increased levels in AD, supporting possible use in patient selection. Commercial assays are available for the measurement of this biomarker [34,35].

CSF and blood chitinase-3-like protein 1 (YKL-40) is expressed in astrocytes besides A β plaques and is connected with tau pathology. CSF YKL-40 is regarded as a biomarker of neuroinflammation or astrogliosis in AD and probably can help in patient selection and prognosis. Commercial assays are already available [25, 36].

Novel fluid biomarkers for synaptic dysfunction

CSF Neurogranin is mainly found in dendritic spines and its function is expressed in post-synaptic signaling pathways. It has been shown to predict disease progression in several studies, even in cognitively normal controls [37, 38]. Its levels are correlated with brain atrophy in subjects with A β pathology. It is regarded that it could be useful as an AD biomarker for patient selection and prognosis. Commercial assays are already available [37].

CSF SNAP-25 and synaptotagmin are synaptic proteins that take part in the mediation of exocytosis of synaptic vesicles for neurotransmitter release. The levels of these proteins are elevated in AD and MCI. They are suggested as potential AD biomarkers for patient selection. Commercial assays are already available for both of them [39].

- *Novel fluid biomarkers for α -Synuclein pathology*

CSF α -synuclein levels may be useful for identifying Lewy Body pathology among AD patients, thus this molecule could be used for patient selection [40].

- *Novel fluid biomarkers for TDP-43 pathology*

Plasma TDP-43 has been found elevated in AD and in pre-MCI patients who progressed to AD. Since commercial assays are already available, **TDP-43** may serve as an AD biomarker for patient selection and prognosis, [41].

Iron metabolism associated novel fluid biomarkers

Since Ferritin plays a major role in brain iron homeostasis, **plasma and CSF Ferritin** may be used as AD biomarkers. CSF Ferritin may become a prognostic biomarker while plasma ferritin could be used for the screening of preclinical AD. Commercial assays are available for both plasma and CSF Ferritin detection [42].

Other neuronal proteins as novel fluid biomarkers

CSF Visinin-like protein 1 (VILIP-1) levels have been proved to be elevated in AD patients in many studies and may be used as prognostic biomarker of incipient cognitive decline, of cognitive decline's and brain atrophy's rates, of progression from MCI to AD and of AD differentiation from other dementias [43]. VILIP-1 is a neuronal calcium sensor protein related to synaptic plasticity in signaling pathways [25]. Commercial assays are already available [25]. **CSF and plasma NF-L (Neurofilament lights)** are promising biomarkers. NF-Ls are expressed in neurons and particularly in axons, where are partly responsible for the transmission of electrical impulses and for normal synaptic function [44]. CSF NF-L levels have been shown to be elevated in AD and MCI patients and to have a linear correlation with cognitive impairment and survival time in AD patients [43]. Plasma NF-L have been found to be increased in pre-symptomatic subjects known to be carriers of AD-causing gene mutations and patients with MCI or AD [45, 46]. They seem also to be correlated with brain atrophy [47]. CSF NF-L could be useful as biomarkers for prognosis, and plasma NF-L could be useful as a non-invasive biomarker for patient selection and prognosis. Commercial and in vitro assays are available [25].

In addition to fluid biomarkers, imaging biomarkers contribute to stratification of patients in disease stages and measurement of disease progression in DMT clinical trials even in the absence of noticeable cognitive impairment [26]. Volumetric MRI, T1-weighted MRI, T2-weighted MRI are useful in structural imaging and quantitative analysis of atrophy in MCI and AD patients. The hippocampus and entorhinal cortex may be the first regions affected by atrophy in MCI and AD. Functional MRIs are used for detecting disease-specific alterations in cognitive functions. Structural and functional MRI findings can predict AD onset in patients with MCI [48, 49, 50]. Amyloid positron emission tomography (PET) is used for detecting the amyloid deposits in preclinical AD and MCI patients and for monitoring the progressive amyloid burden in the brain [51].

The most promising imaging biomarkers seem to be the tau-targeted PET tracers such as Flortaucipir, which are explored in numerous studies [52, 53]. The advent of these tracers enables researchers to investigate the sequence of accumulation of tau and A β in correlation with age and with development of cognitive impairment due to AD. Recent results show that elevated Flortaucipir tau binding is associated with an increased prevalence of cognitive impairment and support further evaluation of tau PET imaging as a possible biomarker for diagnosis, patient staging, and monitoring effects in AD DMT clinical trials [54].

c. Inadequate understanding of the complex pathophysiology of AD: Combination treatments

The complex pathophysiology of AD may be probably unaffected by monotherapy treatments, since all single-agent DMTs have failed to halt the disease progression. Consequently, combination treatments rather than monotherapy may be necessary to delay or halt the multiple cognitive and functional deterioration induced by the disease [55].

Combination trials are different from add-on trials, which are typically used for new therapies in AD comparing a new agent with placebo in patients who are already receiving a background treatment. In combination trials, two drugs are assessed separately, in combination and in comparison with placebo in a 2x2 trial design. Following this methodology investigators can assess the synergistic and individual effects of every drug [56]. The main benefit of this method is that two or more main targets of the disease can be simultaneously addressed (e.g, amyloid and tau) or a single target (e.g. amyloid) can be addressed by two complementary mechanisms of action [55].

Two combination DMTs are currently in phase 3 clinical trials: The ALZT-OPT1 clinical trial, assessing Cromolyn, an anti-amyloid regimen in combination with Ibuprofen, an anti-inflammatory agent in patients with early AD [57]. The second phase 3 combination trial for Gamunex, delivers human albumin through plasma exchange in combination with infusion of intravenous immunoglobulin [56]. This trial targets amyloid in two ways. First, removing and replacing the albumin bound to pathogenic elements of Ab that cross the blood brain barrier by plasma exchange will allow further transfer of A β out of the central nervous system. Second, intravenous immunoglobulin may further increase amyloid clearance by combining plasma exchange with binding (bound?) amyloid [58].

The multiple challenges of treating AD have shifted the current investigational landscape toward combining two agents that target different pathways in parallel, or one long pathway in different points, following the models of successful treatment combinations for other serious diseases, such as HIV and cancer [59].

d. Methodological issues

In addition to the proposed reasons for the failures of trials of DMTs for AD disease-modifying drugs discussed above, issues with clinical trial design and methodology should also be considered [4]. Indeed, new innovative study designs are currently applied.

In placebo-controlled 2x2 trials design, patients are randomized to agent A plus placebo, agent B plus placebo, A plus B and placebo plus placebo [60]. This type of study design is used in combination treatment trials and in add-on studies with some modifications, enabling the simultaneous assessment of different agents and of their combination.

Another trial design which is currently used is the 3-arm study, where patients are randomized to treatment agent A, B, or A plus B [56]. The benefits of this design are that no patient remains untreated and that smaller samples of patients are needed. However this design is less appropriate for later stages of drug development, when every different aspect of every drug must be assessed [56].

Furthermore, several adaptive trials are under way for AD. Adaptive endpoints include drug effects on cognitive and clinical measures, a dose escalation algorithm, novel imaging biomarkers, early disease core and novel fluid biomarkers and later disease cognitive

assessments [61]. Most of novel trials use an adaptive Bayesian design to predict effectiveness or fail of individual agents and adaptively randomize patients to the most successful drugs [62]. Additionally, the interim analyses permit stopping since a predefined signal is detected, hence decision making is accelerated. Adaptive randomization and interim analyses can reduce the size and duration of the trial and prevent advancing to phase 3 whenever data demonstrating clinical efficacy are not detected [63].

Discussion - Conclusion

Given the complexity of AD and the high failure rate of the DMTs in development for AD, treatment of patients remains challenging. The complex pathologic pathways of AD in combination with our incomplete understanding of the relationships among the numerous mechanisms involved in the development of the disease (and the factors accelerating the disease progress?), seem to be mainly responsible for the failure of clinical trials. Targeting well selected or multiple pathologic pathways, earlier initiation of treatment, integration of fluid and imaging biomarkers for patient selection, prognosis, monitoring treatment efficacy, as well as implementation of new innovative study designs are fundamental for the development of effective treatments.

Funding: This research received no external funding.

Acknowledgments: None

Conflicts of Interest: The authors declare no conflict of interest.

REFERENCES

1. Kingston, A.; Comas-Herrera, A.; Jagger, C.; MODEM project. Forecasting the care needs of the older population in England over the next 20 years: estimates from the Population Ageing and Care Simulation (PACSim) modelling study. *Lancet Public Health*. **2018**, *3*(9), e447-e455.
2. Scheltens, P.; Blennow, K.; Breteler, M.M.; de Strooper, B.; Frisoni, G.B.; Salloway, S.; Van der Flier, W.M. Alzheimer's disease. *Lancet*. **2016**, *388*, 505–17.
3. Cummings, J.; Lee, G.; Aaron Ritter, A.; Sabbagh, M.; Zhong, K. Alzheimer's disease drug development pipeline: 2019. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*. **2019**, *5*, 272-293.
4. Anderson, R.M.; Hadjichrysanthou, C.; Evans, S.; Wong, M.M. Why do so many clinical trials of therapies for Alzheimer's disease fail? *Lancet*. **2017**, *25*, 390(10110):2327-2329.
5. Atri A. Current and Future Treatments in Alzheimer's Disease. *Semin Neurol*. **2019**,*39*,227–240.
6. Gauthier, S.; Albert, M.; Fox, N.; Goedert, M.; Kivipelto, M.; Mestre-Ferrandiz, J.; Middleton, L.T. Why has therapy development for dementia failed in the last two decades? *Alzheimers Dement*. **2016**, *12*, 60–64.
7. Cummings, J.L.; Tong, G.; Ballard, C. Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. *Journal of Alzheimer's Disease*. **2019**, *67*, 779–794.
8. Dubois, B.; Hampel, H.; Feldman, H.H.; Scheltens, P.; Aisen, P.; Andrieu, S.; Bakardjian, H.; Benali, H.; Bertram, L.; Blennow, K.; et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. *Alzheimer's & dementia*. **2016**,*12*(3),292–323.
9. Bondi, M.W.; Edmonds, E.C.; Salmon D.P. Alzheimer's Disease: Past, Present, and Future. *J Int Neuropsychol Soc*. **2017**, *23*(9-10), 818–831.
10. Parasrampur, D.A.; Benet, L.Z.; Sharma A. Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations. *The AAPS Journal*. **2018**, *20*, 46.
11. Doody, R.S.; Raman, R.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; He, F.; Sun, X.; Thomas, R.G.; Aisen, P.S.; Alzheimer's Disease Cooperative Study

- Steering Committee, Siemers, E.; Sethuraman, G.; Mohs, R.; Semagacestat Study Group. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. *N Engl J Med.* **2013**, *369*, 341–50.
12. Vandenberghe, R.; Rinne, J.O.; Boada, M.; Katayama, S.; Scheltens, P.; Vellas, B.; Tuchman, M.; Gass, A.; Fiebach, J.B.; Hill, D.; et al. Bapineuzumab 3000 and 3001 Clinical Study Investigators. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. *Alzheimers Res Ther.* **2016**, *8*: 18.
 13. The Lancet Neurology. Solanezumab: too late in mild Alzheimer's disease? *Lancet Neurol.* **2017**, *16*, 97.
 14. Burki, T. Alzheimer's disease research: the future of BACE inhibitors. *Lancet.* **2018**, *23,391(10139)*:2486.
 15. Egan, M.F.; Kost, J.; Voss, T.; Mukai, Y.; Aisen, P.S.; Cummings, J.L.; Tariot, P.N.; Vellas, B.; van Dyck, C.H.; Boada, M.; et al. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. *N Engl J Med.* **2019**, *11*, 380(15):1408-1420.
 16. Henley, D.; Raghavan, N.; Sperling, R.; Aisen, P.; Raman, R.; Romano, G. Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease. *N Engl J Med.* **2019**; *11*, 380(15):1483-1485.
 17. Ower, A.K.; Hadjichrysanthou, C.; Gras, L.; Goudsmit, J.; Anderson, R.M.; de Wolf, F.; Alzheimer's Disease Neuroimaging Initiative. Temporal association patterns and dynamics of amyloid- β and tau in Alzheimer's disease. *Eur J Epidemiol.* **2018**, *33(7)*, 657-666.
 18. Lopez Lopez, C.; Tariot, P.N.; Caputo, A.; Langbaum, J.B.; Liu, F.; Riviere, M.E.; Langlois, C.; Rouzade-Dominguez, M.L.; Zalesak, M.; Hendrix, S.; et al. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. *Alzheimers Dement (N Y).* **2019**, *12*, 5:216-227.
 19. Wisniewski T, Goñi F. Immunotherapeutic approaches for Alzheimer's disease. *Neuron.* **2015**, *18*, 85(6), 1162-76.
 20. Xu, P.; Zhang, M.; Sheng, R.; Ma, Y. Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, A β ₁₋₄₂ aggregation inhibitors and metal-chelating agents for Alzheimer's disease. *Eur J Med Chem.* **2017**, *15(127)*, 174-186.

21. Villemagne, V.L.; Rowe, C.C.; Barnham, K.J.; Cherny, R.; Woodward, M.; Bozinosvski, S.; Salvado, O.; Bourgeat, P.; Perez, K.; Fowler, C.; et al. A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study. *Alzheimers Dement (N Y)*. **2017**, *9*, 3(4), 622-635.
22. Cho, W.H.; Park, J.C.; Kim, D.H.; Kim, M.S.; Lee, S.Y.; Park, H.; Kang, J.H.; Yeon, S.W.; Han, J.S. ID1201, the ethanolic extract of the fruit of *Melia toosendan* ameliorates impairments in spatial learning and reduces levels of amyloid beta in 5XFAD mice. *Neurosci Lett*. **2014**, (7)583,170-5.
23. Cummings J. The National Institute on Aging-Alzheimer's Association framework on Alzheimer's disease: application to clinical trials. *Alzheimers Dement* 2018;15:172–8.
24. Jack, C.R. Jr.; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Dunn, B.; Haeberlein, S.B.; Holtzman, D.M.; Jagust, W.; Jessen, F.; Karlawish, J.; et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. **2018**, *14*, 535–62.
25. Molinuevo, J.L.; Ayton, S.; Batrla, R.; Bednar, M.M.; Bittner, T.; Cummings, J.; Fagan, A.M.; Hampel, H.; Mielke, M.M.; Mikulskis, A.; et al. Current state of Alzheimer's fluid biomarkers. *Acta Neuropathol* **2018**,136, 821–53.
26. Pontecorvo, M.J.; Devous, M.D. Sr.; Navitsky, M.; Lu, M.; Salloway, S.; Schaerf, F.W.; Jennings, D.; Arora, A.K.; McGeehan, A.; Lim, N.C.; et al. 18-AV-1451-A05 investigators. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. *Brain*. **2017**; *140*,748–63.
27. Giau, V.V.; Bagyinszky, E.; An, S.S.A. Potential Fluid Biomarkers for the Diagnosis of Mild Cognitive Impairment. *Int J Mol Sci*. 2019, *25*, 20(17).
28. Hansson, O.; Zetterberg, H.; Buchhave, P.; Londos, E.; Blennow, K.; Minthon, L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. *Lancet Neurol*. **2006**, *5*, 228–234.
29. Isaac, M.; Vamvakas, S.; Abadie, E.; Jonsson, B.; Gispen, C.; Pani, L. Qualification opinion of novel methodologies in the prodementia stage of Alzheimer's disease: cerebrospinal fluid related biomarkers for drugs affecting amyloid burden—regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials. *Eur Neuropsychopharmacol*. **2011**, *21*, 781–788.
30. Lewczuk, P.; Riederer, P.; O'Bryant, S.E.; Verbeek, M.M.; Dubois, B.; Visser, P.J.; Jellinger, K.A.; Engelborghs S.; Ramirez, A.; Parnetti, L.; et al Cerebrospinal fluid and

- blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. *World J Biol Psychiatry*. **2018**, *19*(4), 244-328.
31. Janelidze, S.; Zetterberg, H.; Mattsson, N.; Palmqvist, S.; Vander- stichele, H.; Lindberg, O.; van Westen, D.; Stomrud, E.; Minthon, L.; Blennow, K.; Swedish BioFINDER study group, Hansson, O. CSF A β 42/A β 40 and A β 42/ A β 38 ratios: better diagnostic markers of Alzheimer disease. *Ann Clin Transl Neurol*. **2016**, *3*, 154–165.
32. Shen, Y.; Wang, H.; Sun, Q.; Yao, H.; Keegan, A.P.; Mullan, M.; Wilson, J.; Lista, S.; Leyhe, T.; Laske, C.; et al Increased plasma beta-secretase 1 may predict conversion to Alzheimer's disease dementia in individuals with mild cognitive impairment. *Biol Psychiatry*. **2018**, *83*, 447–455.
33. Chiasserini, D.; Biscetti, L.; Eusebi, P.; Salvadori, N.; Frattini, G.; Simoni, S.; De Roeck, N.; Tambasco, N.; Stoops, E.; Vanderstichele, H.; et al. Differential role of CSF fatty acid binding protein 3, α -synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. *Alzheimers Res Ther* . **2017**, *9*, 52.
34. Gispert JD, Suárez-Calvet M, Monté GC, Tucholka A, Falcon C, Rojas S et al (2016) Cerebrospinal fluid's TREM2 levels are associated with gray matter volume increases and reduced diversity in early Alzheimer's disease. *Alzheimers Dement* 12:1259–1272.
35. Tan, Y.J.; Ng, A.S.L.; Vipin, A.; Lim, J.K.W.; Chander, R.J.; Ji, F.; Qiu, Y.; Ting, S.K.S.; Hameed, S.; Lee T.; Zeng, L.; et al. Higher peripheral TREM2 mRNA levels relate to cognitive deficits and hippocampal atrophy in Alzheimer's disease and amnesic mild cognitive impairment. *J Alzheimers Dis*. 2017, **58**, 413– 423.
36. Querol-Vilaseca, M.; Colom-Cadena, M.; Pegueroles, J.; San Martín- Paniello, C.; Clarimon, J.; Belbin, O.; Fortea, J.; Lleo, A. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. *J Neuroinflammation* **2017**, *14*, 118.
37. Tarawneh, R.; D'Angelo, G.; Crimmins, D.; Herries, E.; Griest, T.; Fagan, A.M.; Zipfel, G.J.; Ladenson, J.H.; Morris, J.C.; Holtzman, D.M. Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. *JAMA Neurol*. **2016**, *73*, 561–571.
38. Mavroudis, I.A.; Petridis, F.; Chatzikonstantinou, S.; Kazis, D. A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer's disease and mild cognitive impairment. *Aging Clin Exp Res*. **2019**, 28.

39. Sutphen, C.L.; McCue, L.; Herries, E.M.; Xiong, C.; Ladenson, J.H.; Holtzman, D.M. Fagan, A.M.; ADNI. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. *Alzheimers Dement.* **2018**, *14*, 869–879.
40. Toledo, J.B.; Kor, A.; Shaw, L.M.; Trojanowski, J.Q.; Zhang, J. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease. *Acta Neuropathol.* **2013**, *126*, 683–697.
41. Williams, S.M.; Schulz, P.; Rosenberry, T.L.; Caselli, R.J.; Sierks, M.R. Blood-based oligomeric and other protein variant bio- markers to facilitate pre-symptomatic diagnosis and staging of Alzheimer's disease. *J Alzheimers Dis.* **2017**, *58*, 23–35.
42. Ayton, S.; Faux, N.G.; Bush, A.I. Association of cerebrospinal fluid ferritin level with preclinical cognitive decline in APOE-ε4 carriers. *JAMA Neurol* **2017**, *74*, 122–125.
43. Tarawneh, R.; Lee, J.M.; Ladenson, J.H.; Morris, J.C.; Holtzman, D.M. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. *Neurology* **2012**, *78*, 709–719.
44. Zetterberg, H. Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration. *Neuron.* **2016**, *6*, 91(1), 1-3.
45. Zetterberg, H.; Skillbäck, T.; Mattsson, N.; Trojanowski, J.Q.; Portelius, E.; Shaw, L.M.; Weiner, M.W.; Blennow, K.; Alzheimer's Disease Neuroimaging Initiative. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. *JAMA Neurol.* **2016**, *73*, 60–67.
46. Mattsson, N.; Andreasson, U.; Zetterberg, H.; Blennow, K.; Alzheimer's Disease Neuroimaging Initiative. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. *JAMA Neurol.* **2017**, *1*, 74(5), 557-566.
47. Zhou, W.; Zhang, J.; Ye, F.; Xu, G.; Su, H.; Su, Y.; Zhang, X.; Alzheimer's Disease Neuroimaging Initiative. Plasma neuro filament light chain levels in Alzheimer's disease. *Neurosci Lett.* **2017**, *650*, 60–64.
48. Yuan, A.; Rao, M.V.; Veeranna Nixon, R.A. Neurofilaments and neurofilament proteins in health and disease. *Cold Spring Harb Perspect Biol.* **2017**, *9*, a018309.
49. Mak, E.; Gabel, S.; Mirette, H.; Su, L.; Williams, G.B.; Waldman, A.; Wells, K.; Ritchie, K.; Ritchie, C.; O'Brien, J. Structural neuroimaging in preclinical dementia: From microstructural deficits and grey matter atrophy to macroscale connectomic changes. *Ageing Res. Rev.* **2017**, *35*, 250–264.

50. Albert, M.; Zhu, Y.; Moghekar, A.; Mori, S.; Miller, M.I.; Soldan, A.; Pettigrew, C.; Selnes, O.; Li, S.; Wang, M.C. Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years. *Brain A J. Neurol.* **2018**, *141*, 877–887.
- [
51. Yin, C.; Li, S.; Zhao, W.; Feng, J. Brain imaging of mild cognitive impairment and Alzheimer's disease. *Neural Regen Res.* **2013**, *8*, 435–444.
52. Rabinovici, G.D.; Gatsonis, C.; Apgar, C.; Chaudhary, K.; Gareen, I.; Hanna, L.; Hendrix, J.; Hillner, B.E.; Olson, C.; Lesman-Segev, O.H.; et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. *Jama* **2019**, *321*, 1286–1294.
53. Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J et al. Tau and Ab imaging, CSR measures, and cog- nition in Alzheimer's disease. *Sci Transl Med* 2016; 8: 338ra66.
54. Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. *Ann Neurol* 2016; 79: 110–19.
55. Pontecorvo, M.J.; Devous, M.D. Sr.; Navitsky, M.; Lu, M.; Salloway, S.; Schaerf, F.W.; Jennings, D.; Arora, A.K.; McGeehan, A.; Lim, NC.; et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. *Brain.* **2017**, *1*, 140(3):748-763.
56. Cummings, J.L.; Tong, G.; Ballard C. Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. *Journal of Alzheimer's Disease.* **2019**, *67*, 779–794
57. Zhang, C.; Griciuc, A.; Hudry, E.; Wan, Y.; Quinti, L.; Ward, J.; Forte, A.M.; Shen, X.; Ran, C.; Elmaleh, D.R.; Tanzi, R.E. Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β -Protein by Promoting Microglial Phagocytosis. *Sci Rep.* **2018**, *18*, 8(1),1144.
58. Boada, E.; Ramos-Fernandez, E.; Guivernau, B.; Munoz, F.J.; Costa, M.; Ortiz, A.M.; Jorquera, J.I.; Nunez, L.; Torres, M.; Paez, A. Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: rationale and treatment approach of the AMBAR

- (Alzheimer Management By Albumin Replacement) study. *Neurologia*. **2016**, *31*, 473-481.
59. Tomaszewski, S.; Gauthier, S.; Wimo, A.; Rosa-Neto, P. Combination therapy of anti-tau and anti-amyloid drugs for disease modification in early-stage Alzheimer's disease: socio-economic considerations modeled on treatments for tuberculosis, HIV/AIDS and breast cancer. *J Prev Alzheimers Dis*. **2016**, *3*, 164-172.
60. Evans, S.R. Clinical trial structures. *J Exp Stroke Transl Med*. **2010**, *3*, 8-18.
61. Bateman, R.J.; Benzinger, T.L.; Berry, S.; Clifford, D.B.; Duggan, C.; Fagan, A.M.; Fanning, K.; Farlow, M.R.; Hassenstab, J.; McDade, E.M.; et al. The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model. *Alzheimers Dement*. **2017**, *13*, 8-19.
62. Ritchie, C.W.; Molinuevo, J.L.; Truyen, L.; Satlin, A.; Van der Geyten, S.; Lovestone, S. European Prevention of Alzheimer's Dementia Consortium Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. *Lancet Psychiatry*. **2016**, *3*, 179-186.
63. Satlin, A.; Wang, J.; Logovinsky, V.; Berry, S.; Swanson, C.; Dhadda, S.; Berry, D.A. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease. *Alzheimers Dement (N Y)*. 2016 Feb 4;2(1):1-12.